Morioka, Japan · Founded 2014 · Privately Held (backing)
Developer of in-vitro diagnostic agents and medical devices designed to offer the prognosis of endometriosis progression. Cellspect is based in Morioka, Japan and was founded in 2014. Its last reported valuation was $142 million in May 2019. It has raised $22.6 million.
Last reported valuation
$142.1M
Oct 2026
Priced at
—
Total raised
$22.6M
Last round
—
Cap table — not yet on record
Cellspect's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Cellspect with a free account
·The complete investor list: 15 names
·Watch Cellspect: the Monday email on marks, rounds and moves
